Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections

Launched by SINGAPORE GENERAL HOSPITAL · Jul 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to guide antibiotic treatment for patients with tough-to-treat bacterial infections that can lead to serious conditions like sepsis. The researchers want to see if using a method called Therapeutic Drug Monitoring (TDM) can help improve survival rates compared to standard antibiotic therapy. The goal is to find out if TDM can reduce the number of patients who die within 14 days of treatment by 6%. In this trial, some patients will receive TDM-guided antibiotics, while others will receive the usual treatment without the benefit of TDM information.

To participate in this trial, individuals must be at least 16 years old and currently receiving specific antibiotics through an IV for at least three days. However, pregnant individuals, those on palliative care, or those who are not expected to live longer than 48 hours will not be eligible. Participants can expect to have their antibiotic levels monitored through blood tests during their treatment, which aims to ensure they receive the most effective doses. This research is important because it could lead to better treatment options for patients facing difficult infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 16 years or older
• • Receive intravenous therapy of the study antibiotics
• • Antibiotic treatment should be aimed for at least 3 days at time of inclusion
• Exclusion Criteria:
• • Pregnancy
• • Antibiotics cessation before first blood sample collection
• • Receiving antibiotics only as prophylaxis
• • On palliative care or with less than 48 hours of life expectancy